US 7,517,533 B2
	Pseudomonas aeruginosa antigens
Allan W. Cripps, Nicholls (Australia); Jennelle M. Kyd, McKellar (Australia); and Linda D. Thomas, Aranda (Australia)
Assigned to The University of Canberra, Belconnen (Australia)
Appl. No. 10/148,414 PCT Filed Dec. 04, 2000, PCT No. PCT/GB00/04625 § 371(c)(1), (2), (4) Date Dec. 02, 2002, PCT Pub. No. WO01/40473, PCT Pub. Date Jun. 07, 2001.
Claims priority of application No. 9928676.7 (GB), filed on Dec. 03, 1999.
Prior Publication US 2004/0071713 A1, Apr. 15, 2004
Int. Cl. A61K 39/02 (2006.01); A61K 39/00 (2006.01); A61K 39/108 (2006.01); A61K 38/00 (2006.01); A61K 38/16 (2006.01); A01N 37/08 (2006.01)

U.S. Cl. 424—260.1  [424/234.1; 424/190.1; 424/184.1; 514/2; 530/350; 530/300; 530/825; 530/806]

5 Claims

1. A vaccine composition, said composition comprising an isolated immunogenic Pseudomonas aeruginosa protein which has a molecular weight of about 40 kDa as determined by SDS-PAGE under reducing conditions and wherein the amino terminal sequence of said protein is the amino acid sequence set forth in SEQ ID NO: 5, said vaccine composition comprising a pharmaceutically acceptable excipient and an adjuvant and wherein said vaccine composition is capable of inducing lung clearance after pulmonary infection by homologous Pseudomonas aeruginosa in a subject immunized with said vaccine composition.